Bioequivalence Testing: The Stats Behind Generic Drug Approvals (Ep. 57)

Episode 57

0:00-24:13

In this episode I discuss bioequivalence testing and how it was developed to support generic drug approvals, but is now a mainstream tool for all of drug development. I discuss the basics of what bioequivalence means, how the studies are designed, and then how to perform the statistical analysis. I end with some examples of how this can be used for both generic drug and innovator drugs to support labeling. Links discussed in the show: FDA Draft Guidance: Statistical Approaches to Establishing Bioequivalence (Dec 2022) – Excellent detail on methods, models, and SAS examples. FDA Guidance: Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA. Article: “Bioequivalence of generic drugs: a simple explanation for clinicians” (Andrade, 2015) – Great for the 80-125% intuition. R-script with example BE analysis (Be sure to copy this text into a file and name it "BE-example.R" then you can run it on your local R instance. You can connect with Nathan on LinkedIn and send me a message Send Nathan a message Sign up for Nathan’s newsletter Copyright Teuscher Solutions LLC All Rights Reserved

Publisher

Clinical Pharmacology Podcast with Nathan Teuscher

Link

podcasters.spotify.com/pod/show/clinical-pharmacology/episodes/Bioequivalence-Testing-The-Stats-Behind-Generic-Drug-Approvals-Ep--57-e3jqc97

Published

May 25, 2026

Duration

24 min

Format

Podcast

Category

Issues · Science

Source

RSS feed

Host

Nathan Teuscher

CP

Clinical Pharmacology Podcast with Nathan Teuscher

@clinicalpharmacologypodcastw

#bioequivalencetesting #stats #genericdrugapprovals #lifesciences

The Nile